New hope for hard-to-treat lymphoma: experimental drug combo enters phase 3 trial
Disease control
Not yet recruiting
This phase 3 trial compares a new drug (SCTB35) plus chemotherapy against a standard drug (rituximab) plus chemotherapy in about 101 adults with diffuse large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if the new combination works b…
Phase: PHASE3 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC